Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer
Giordano, Antonio, Liu, Yueying, Armeson, Kent, Park, Yeonhee, Ridinger, Maya, Erlander, Mark, Reuben, James, Britten, Carolyn, Kappler, Christiana, Yeh, Elizabeth, Ethier, Stephen
Published in PloS one (21.11.2019)
Published in PloS one (21.11.2019)
Get full text
Journal Article
Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
Affatato, Roberta, Chiappa, Michela, Guffanti, Federica, Ricci, Francesca, Formenti, Laura, Fruscio, Robert, Jaconi, Marta, Ridinger, Maya, Erlander, Mark, Damia, Giovanna
Published in Therapeutic advances in medical oncology (2022)
Published in Therapeutic advances in medical oncology (2022)
Get full text
Journal Article
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
Chiappa, Michela, Decio, Alessandra, Guarrera, Luca, Mengoli, Ilaria, Karki, Anju, Yemane, Divora, Ghilardi, Carmen, Scanziani, Eugenio, Canesi, Simone, Barbera, Maria C., Craparotta, Ilaria, Bolis, Marco, Fruscio, Robert, Grasselli, Chiara, Ceruti, Tommaso, Zucchetti, Massimo, Patterson, Jesse C., Lu, Robin A., Yaffe, Micheal B., Ridinger, Maya, Damia, Giovanna, Guffanti, Federica
Published in Cell death & disease (22.07.2024)
Published in Cell death & disease (22.07.2024)
Get full text
Journal Article
Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy
Saison-Ridinger, Maya, DelGiorno, Kathleen E, Zhang, Tejia, Kraus, Annabelle, French, Randall, Jaquish, Dawn, Tsui, Crystal, Erikson, Galina, Spike, Benjamin T, Shokhirev, Maxim N, Liddle, Christopher, Yu, Ruth T, Downes, Michael, Evans, Ronald M, Saghatelian, Alan, Lowy, Andrew M, Wahl, Geoffrey M
Published in PloS one (06.12.2017)
Published in PloS one (06.12.2017)
Get full text
Journal Article
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring
Shi, Yu, Gao, Weina, Lytle, Nikki K., Huang, Peiwu, Yuan, Xiao, Dann, Amanda M., Ridinger-Saison, Maya, DelGiorno, Kathleen E., Antal, Corina E., Liang, Gaoyang, Atkins, Annette R., Erikson, Galina, Sun, Huaiyu, Meisenhelder, Jill, Terenziani, Elena, Woo, Gyunghwi, Fang, Linjing, Santisakultarm, Thom P., Manor, Uri, Xu, Ruilian, Becerra, Carlos R., Borazanci, Erkut, Von Hoff, Daniel D., Grandgenett, Paul M., Hollingsworth, Michael A., Leblanc, Mathias, Umetsu, Sarah E., Collisson, Eric A., Scadeng, Miriam, Lowy, Andrew M., Donahue, Timothy R., Reya, Tannishtha, Downes, Michael, Evans, Ronald M., Wahl, Geoffrey M., Pawson, Tony, Tian, Ruijun, Hunter, Tony
Published in Nature (London) (01.05.2019)
Published in Nature (London) (01.05.2019)
Get full text
Journal Article
Abstract 425: Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer
Sharma, Manish R., Isaac, Daniel, Ramaekers, Ryan, Ridinger, Maya, Erlander, Mark, Mendelsohn, Lawrence
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal Cancer (mCRC)
Ahn, Daniel H., Ridinger, Maya, Erlander, Mark, Bekaii-Saab, Tanios S., Lenz, Heinz-Josef
Published in Journal of clinical oncology (20.01.2021)
Published in Journal of clinical oncology (20.01.2021)
Get full text
Journal Article
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Zeidan, Amer M, Ridinger, Maya, Lin, Tara L, Becker, Pamela S, Schiller, Gary J, Patel, Prapti A, Spira, Alexander I, Tsai, Michaela L, Samuëlsz, Errin, Silberman, Sandra L, Erlander, Mark, Wang, Eunice S
Published in Clinical cancer research (01.12.2020)
Published in Clinical cancer research (01.12.2020)
Get full text
Journal Article
Abstract 945: In vivo anti-tumor activity of onvansertib, a PLK1 inhibitor, combined with gemcitabine or carboplatin in platinum- resistant ovarian carcinoma patient-derived xenograft models
Chiappa, Michela, Guffanti, Federica, Mengoli, Ilaria, Ridinger, Maya, Damia, Giovanna
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Predictive Biomarkers of Response to the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Decitabine in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Zeidan, Amer M., Ridinger, Maya, Croucher, Peter J.P., Samuëlsz, Errin, Erlander, Mark, Ruffner, Katherine L., Wang, Eunice S.
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Abstract A43: Plasma-derived circulating tumor DNA (ctDNA) as a surrogate biomarker for treatment response with the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with LDAC or decitabine in acute myeloid leukemia (AML)
Samuelsz, Errin, Ridinger, Maya, Erlander, Mark, Hassaine, Latifa, Luebbermann, Marion, Ross, Brittany
Published in Clinical cancer research (01.06.2020)
Published in Clinical cancer research (01.06.2020)
Get full text
Journal Article
A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer (mCRC) in patients with a KRAS mutation
Lenz, Heinz-Josef, Ahn, Daniel H., Ridinger, Maya, Erlander, Mark G., Barzi, Afsaneh
Published in Journal of clinical oncology (01.02.2020)
Published in Journal of clinical oncology (01.02.2020)
Get full text
Journal Article
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy
Wang, Dong, Veo, Bethany, Pierce, Angela, Fosmire, Susan, Madhavan, Krishna, Balakrishnan, Ilango, Donson, Andrew, Alimova, Irina, Sullivan, Kelly D, Joshi, Molishree, Erlander, Mark, Ridinger, Maya, Foreman, Nicholas K, Venkataraman, Sujatha, Vibhakar, Rajeev
Published in Neuro-oncology (Charlottesville, Va.) (12.03.2022)
Published in Neuro-oncology (Charlottesville, Va.) (12.03.2022)
Get full text
Journal Article
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study
Ahn, Daniel H, Barzi, Afsaneh, Ridinger, Maya, Samuëlsz, Errin, Subramanian, Ramanand A, Croucher, Peter J P, Smeal, Tod, Kabbinavar, Fairooz F, Lenz, Heinz-Josef
Published in Clinical cancer research (15.05.2024)
Published in Clinical cancer research (15.05.2024)
Get full text
Journal Article
Abstract CT161: A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Einstein, David J., Choudhury, Atish, Saylor, Philip, Werner, Lillian, Erlander, Mark, Ridinger, Maya, Bubley, Glenn
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Einstein, David Johnson, Choudhury, Atish Dipankar, Saylor, Philip James, Patterson, Jesse Christopher, Croucher, Peter, Ridinger, Maya, Erlander, Mark G., Yaffe, Michael B., Bubley, Glenn
Published in Journal of clinical oncology (20.02.2022)
Published in Journal of clinical oncology (20.02.2022)
Get full text
Journal Article
Abstract 2019: Oxidative phosphorylation (OXPHOS) dependency predicts response to the Polo-like kinase 1 (PLK1) inhibitor onvansertib in a phase 1b/2 of relapsed/refractory acute myeloid leukemia (R/R AML)
Croucher, Peter JP, Samuelsz, Errin, Hassaine, Latifa, Ross, Brittany, Luebbermann, Marion, Ridinger, Maya, Erlander, Mark
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
Abstract CT235: A phase 1b/2 study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC)
Barzi, Afsaneh, Lenz, Heinz-Josef, Samuëlsz, Errin, Ridinger, Maya, Erlander, Mark, Bekaii-Saab, Tanios S., Ahn, Daniel H.
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC)
Ahn, Daniel H., Barzi, Afsaneh, Ridinger, Maya, Samuelsz, Errin, Erlander, Mark G., Bekaii-Saab, Tanios S., Lenz, Heinz-Josef
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial
Ahn, Daniel H, Ridinger, Maya, Cannon, Timothy L, Mendelsohn, Lawrence, Starr, Jason S, Hubbard, Joleen M, Kasi, Anup, Barzi, Afsaneh, Samuëlsz, Errin, Karki, Anju, Subramanian, Ramanand A, Yemane, Divora, Kim, Roy, Wu, Chu-Chiao, Croucher, Peter J P, Smeal, Tod, Kabbinavar, Fairooz F, Lenz, Heinz-Josef
Published in Journal of clinical oncology (30.10.2024)
Published in Journal of clinical oncology (30.10.2024)
Get full text
Journal Article